Sagimet Biosciences Inc. (SGMT) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 13 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 12, 2026before open 43 8-K
Q2 FY2026Tue, Aug 11, 2026before open 42 8-K
Q1 FY2026Tue, May 12, 2026before open 42 8-K
Q4 FY2025Wed, Mar 11, 2026before open 70 8-K
Q3 FY2025Thu, Nov 13, 2025before open 44 8-K
Q2 FY2025Wed, Aug 13, 2025before open 44 8-K
Q1 FY2025Thu, May 8, 2025before open 38 8-K
Q4 FY2024Wed, Mar 12, 2025before open 71 8-K

What they guided beta

Q3 FY2026 "Pro forma cash and investments balance of approximately $356 million as of September 30, expected to fund current operations through mid-2029 including through readout of data from the denifanstat AURORA Phase 3 clinical trial in moderate to severe acne and potential NDA submission" exhibit
Q3 FY2026 "The trial is intended to support a potential U.S. New Drug Application (NDA), with topline data expected in the second half of 2027." exhibit
Q3 FY2026 "Phase 2 doses have been identified, and the Company anticipates initiating the Phase 2 clinical trial of TVB-3567 in moderate to severe acne patients before the end of 2026." exhibit
Q3 FY2026 "Fall Clinical Dermatology 2026: In October 2026, Sagimet presented the positive 52-week results from Ascletis’ Phase 3 open-label extension trial, previously presented by Ascletis at EADV 2026, together with mechanistic data supporting denifanstat’s differentiated approach to targeting key aspects of acne pathogenesis: sebum production and inflammation ( here )." exhibit
Q3 FY2026 "Denifanstat: Continue enrollment in the U.S. AURORA Phase 3 clinical trial in moderate to severe acne, with topline data expected in the second half of 2027." exhibit
Q2 FY2026 "Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured equity financing with gross proceeds of $175.0 million in April 2026 Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 trial in moderate to sev" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SGMT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SGMT

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

SGMT earnings date badge

HTML

<a href="https://veritasdata.dev/company/SGMT/"><img src="https://veritasdata.dev/embed/SGMT.svg" alt="SGMT earnings date" width="240" height="56"></a>

Markdown

[![SGMT earnings date](https://veritasdata.dev/embed/SGMT.svg)](https://veritasdata.dev/company/SGMT/)

Script

<script async src="https://veritasdata.dev/embed/SGMT.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SGMT"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.